Theriva Biologics (TOVX) Operating Income (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Operating Income of -$2.1 million for Q1 2026, up 51.85% year-over-year from -$1.4 million in Q1 2025, and down 3.1% quarter-over-quarter from -$2.1 million in Q4 2025.
Theriva Biologics (TOVX) Operating Income (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Operating Income for 16 consecutive years, with -$2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 51.85% year-over-year to -$2.1 million; the TTM figure through Mar 2026 stood at -$21.8 million (up 14.23% YoY), while the FY2025 annual figure was -$24.1 million, up 8.71% from the prior year.
- Operating Income declined to -$2.1 million in Q1 2026 per TOVX's latest filing, from -$2.1 million in the prior quarter.
- Across five years, Operating Income topped out at -$2.1 million in Q4 2025 and bottomed at -$13.1 million in Q2 2025.
- Historically, Operating Income has averaged -$5.6 million across 5 years, with a median of -$5.0 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Income slumped 86.98% — and 2025, when it soared 54.96%.
- Theriva Biologics' Operating Income stood at -$7.3 million in 2022, then rose by 15.03% to -$6.2 million in 2023, then grew by 26.33% to -$4.6 million in 2024, then jumped by 54.96% to -$2.1 million in 2025, then slipped by 3.1% to -$2.1 million in 2026.
- Business Quant data shows TOVX's Operating Income at -$2.1 million in Q1 2026, -$2.1 million in Q4 2025, and -$4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | -3.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.30 Mn |
| Mar 31, 2026 | -2.13 Mn |
| Dec 31, 2025 | -2.06 Mn |
| Sep 30, 2025 | -4.44 Mn |
| Jun 30, 2025 | -13.13 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Dec 31, 2024 | -4.58 Mn |
| Sep 30, 2024 | -7.89 Mn |
| Jun 30, 2024 | -8.49 Mn |
| Mar 31, 2024 | -5.39 Mn |
| Dec 31, 2023 | -6.22 Mn |
| Sep 30, 2023 | -4.22 Mn |
| Jun 30, 2023 | -5.82 Mn |
| Mar 31, 2023 | -5.18 Mn |
| Dec 31, 2022 | -7.32 Mn |
| Sep 30, 2022 | -4.99 Mn |
| Jun 30, 2022 | -5.03 Mn |
| Mar 31, 2022 | -4.25 Mn |
| Dec 31, 2021 | -5.27 Mn |
| Sep 30, 2021 | -3.28 Mn |